Reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-28. Numbers and descriptions here follow the published literature rather than marketing material.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Compound class | Synthetic tetrapeptide | Not a natural free peptide |
| Research origin | Russian gerontology institutes | Developed during the 1990s |
| Main research claim | Telomerase activation | Evidence mainly from cultured cells |
| Regulatory status | Not an approved drug | Handled as a research material |
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
Storage and handling follow conventional peptide practice. Lyophilized epitalon is typically kept refrigerated or frozen, protected from moisture and light, and allowed to equilibrate to room temperature before opening to avoid condensation. Once dissolved, aqueous solutions are usually stored cold and used within a short period, since dilute peptide solutions can support microbial growth and may slowly degrade. The absence of cysteine and methionine reduces, but does not eliminate, oxidation concerns during long-term storage.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
==== Blebs ==== Blebs are spherical membrane protrusions that are involved in both apoptosis and cell movement. The driving force behind bleb extension is hydrostatic pressure, rather than actin filament elongation which drives lamellipodia, filopodia and invadopodia extension. Blebs are formed by actomyosin contraction, which causes the delamination of the plasma membrane from the actin cortex or a focal rupture of the actin cortex. They are then stabilized via actin cortex reassembly and finally retracted via actomyosin contraction. In migrating cells a front-rear polarity is established, with bleb formation restricted to the leading edge, allowing for directed movement.
=== Label-free drug screening === Thermofluor has been extensively used in drug screening campaigns. Because Thermofluor detects high affinity binding sites for small molecules on proteins, it can find hits that bind to active site subsites, cofactor sites, or allosteric binding sites with equal efficacy. The method typically requires the use of screening compound concentrations at >10x the desired binding threshold. Setting 5 μM as a reasonable hit threshold consequently requires a test ligand concentration of 50 to 100 μM in the sample well. For most drug compound libraries, where many compounds are not soluble beyond ~100 μM, screening multiple compounds is consequently not feasible owing to solubility issues. Thermofluor screens do not require the development of custom screening reagents (e.g. cleavable substrate analogs), do not require any radioactive reagents, and are generally less sensitive to the effects of compounds that are chemically reactive with protein active site residues, and that consequently show up as undesirable hits in enzyme activity screens.
. This generates a periodic restoring force that confines the beam in the two spatial directions orthogonal to the direction of propagation. The technique can be implemented using photolithography; two chips created by that technique placed face to face separated by 1 mm create an electron trap.
In 1968, a period of political liberalization took place in Czechoslovakia called the Prague Spring. An "Action Program" of reforms included increasing freedom of the press, freedom of speech and freedom of movement, along with an economic emphasis on consumer goods, the possibility of a multiparty government, limitations on the power of the secret police, and potential withdrawal from the Warsaw Pact. In answer to the Prague Spring, on 20 August 1968, the Soviet Army, together with most of their Warsaw Pact allies, invaded Czechoslovakia. The invasion was followed by a wave of emigration, including an estimated 70,000 Czechs and Slovaks initially fleeing, with the total eventually reaching 300,000. The invasion sparked intense protests from Yugoslavia, Romania, China, and from Western European countries.
Sources: en.wikipedia.org
It was published by Carl Linnaeus in 1753 with Tulipa gesneriana L. as the type species. Tulipa is a genus of the lily family, Liliaceae, once one of the largest families of monocots, but which molecular phylogenetics has reduced to a monophyletic grouping with only 15 genera. Within Liliaceae, Tulipa is placed within Lilioideae, one of three subfamilies, with two tribes. Tribe Lilieae includes seven other genera in addition to Tulipa.
The neurotransmitter serotonin, a non-selective serotonin receptor agonist, strongly increases oxytocin levels, by up to 12-fold, when given via intracerebroventricular injection in rodents. This can be blocked by various serotonin receptor antagonists. Selective serotonin 5-HT1A receptor agonists like 8-OH-DPAT, buspirone, and ipsapirone increase oxytocin levels in rodents. Both 8-OH-DPAT and buspirone maximally increased oxytocin levels by around 9-fold, whereas ipsapirone increased oxytocin levels by only around 3-fold. Similarly to serotonin 5-HT1A receptor agonists, the serotonin 5-HT2 receptor agonist DOI increases oxytocin levels in rodents, with a maximal increase of around 5- to 10-fold depending on the dose. The serotonin 5-HT2A receptor antagonist ketanserin reduced the increase in oxytocin levels induced by DOI by about 90%, while addition of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist LY-53857 fully blocked the increase. The non-selective but preferential serotonin 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) maximally increased oxytocin levels by around 6-fold, with the increases minimally affected by ketanserin but abolished by non-selective serotonin 5-HT2 receptor antagonists including LY-53857, mianserin, and metergoline. Another non-selective but preferential serotonin 5-HT2C receptor agonist, MK-212, robustly increases oxytocin levels in rodents as well. The serotonin 5-HT3 receptor agonists SR-57277 and m-CPBG and the serotonin 5-HT4 receptor agonist RS-67506 increase oxytocin levels maximally by several-fold in rodents.
There are different immune responses that the body could have depending on where the polymer is placed. For example, in drug delivery systems (DDS), PLGA and PLA implants with high surface area and low volume of injection can increase one's chance of immune response as the polymers degrade in the body.
Sources: en.wikipedia.org
Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.
That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.
It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.